Loading…
Adlai Nortye Ltd. is projected to rise to $23.84 by 2027, a +83% move from its current price of $13.00. ANL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $12.36 | $13.02 | $13.70 | +0.13% |
| Aug 3 | $12.12 | $13.03 | $14.02 | +0.25% |
| Aug 4 | $11.94 | $13.05 | $14.26 | +0.38% |
| Aug 5 | $11.79 | $13.07 | $14.48 | +0.51% |
| Aug 6 | $11.66 | $13.08 | $14.68 | +0.64% |
| Aug 7 | $11.55 | $13.10 | $14.86 | +0.76% |
| Aug 8 | $11.45 | $13.12 | $15.03 | +0.89% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.45 | $13.12 | $15.03 | +0.89% |
| Week 2 | $10.92 | $13.23 | $16.04 | +1.79% |
| Week 3 | $10.55 | $13.35 | $16.89 | +2.70% |
| Week 4 | $10.26 | $13.47 | $17.68 | +3.61% |
| Week 5 | $10.03 | $13.59 | $18.42 | +4.53% |
| Week 6 | $9.83 | $13.71 | $19.13 | +5.47% |
| Week 7 | $9.65 | $13.83 | $19.82 | +6.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adlai Nortye Ltd. is a healthcare company operating as a clinical-stage enterprise focused on developing pharmaceutical products. Its pipeline includes AN0025, a small molecule EP4 antagonist which is in phase Ib and being studied in radiotherapy/chemoradiotherapy combinations for rectum cancer and esophageal cancer; and a phase II trial for patients with moderate to high-risk rectal cancer.
The company also advances AN9025, an oral small molecule pan-RAS(ON) inhibitor in phase 1a trials for RAS-mutant cancers, AN4035, a CEACAM5-targeting antibody drug conjugate, AN8025, a tri-specific antibody fusion protein in phase Ia, and AN4005, a small-molecule PD-L1 inhibitor in phase 1b clinical trial to activate cancer immunity. In addition, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd.
was founded in 2004 and is headquartered in North Brunswick, New Jersey.
ANL is the ticker for Adlai Nortye Ltd., a healthcare company with a current price of $13.00 and a market capitalization of $837.17M, ranked 2493. The asset sits in the healthcare sector, with a diversified pipeline targeting cancer pathways and immune modulation. The price outlook conveyed in the forecast shows a path of growth in the coming years with notable upside in the long term.
A major floor 50.3% below — a decisive break under it would weaken the trend.
The nearest floor, 29.2% below — buyers have tended to step in here.
Price is pressing into resistance (2.0% away) — a breakout level to watch.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key ANL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.57 | Buy | $12.72 | Buy |
| MA 10 | $12.68 | Buy | $12.42 | Buy |
| MA 20 | $11.56 | Buy | $11.91 | Buy |
| MA 50 | $11.13 | Buy | $11.45 | Buy |
| MA 100 | $11.26 | Buy | $10.57 | Buy |
| MA 200 | $7.48 | Buy | $8.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.91 | Neutral |
| Stoch RSI (14) | 78.31 | Neutral |
| CCI (20) | 85.55 | Neutral |
| Williams %R (14) | -6.40 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 22.30 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 93.60 | Sell |
| TRIX (15) | 0.52 | Buy |
| Awesome (5,34) | 1.44 | Buy |
| Ultimate (7,14,28) | 56.13 | Neutral |
| Momentum (10) | 1.47 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 12.63 | Buy |
| ADX (14) | 14.09 | Neutral |
| ATR (14) | 0.55 | Info |
The near-term technical picture is bullish. RSI(14) is 60, signaling modest positive momentum. The stock is trading with a 50-day simple moving average of $11.08 and a 200-day simple moving average of $7.42, placing current levels above the long-term trend.
Support is at $9.20 and resistance at $13.26, suggesting a tight range around the current area. Over the last 30 days, the price has ranged from a low of $9.17 to a high of $18.44, reflecting volatility within a broad trading band. Annualized volatility stands at 100%, highlighting substantial price fluctuations in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.38 | $13.00 | $23.78 | 0% | Neutral | |
| $17.49 | $23.84 | $35.09 | +83% | Bullish | |
| $20.49 | $29.61 | $46.41 | +128% | Bullish | |
| $20.78 | $31.57 | $51.91 | +143% | Bullish | |
| $22.06 | $35.06 | $59.95 | +170% | Bullish | |
| $23.12 | $38.31 | $67.79 | +195% | Bullish | |
| $24.48 | $42.22 | $76.98 | +225% | Bullish | |
| $34.28 | $61.43 | $115.06 | +373% | Bullish | |
| $40.87 | $76.02 | $145.92 | +485% | Bullish | |
| $42.77 | $82.48 | $161.95 | +534% | Bullish | |
| $59.91 | $133.12 | $286.77 | +924% | Bullish | |
| $120.05 | $266.78 | $613.60 | +19.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.38 | $13.00 | $17.44 | +0.00% |
| September 2026 | $11.85 | $14.39 | $18.23 | +10.70% |
| October 2026 | $11.86 | $14.59 | $18.84 | +1.40% |
| November 2026 | $13.07 | $16.26 | $21.31 | +11.40% |
| December 2026 | $14.24 | $17.89 | $23.78 | +10.05% |
Click any year to see its month-by-month ANL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Adlai Nortye Ltd.'s 2026 outlook centres on $13.00, within a $1.38 to $23.78 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ANL could reach as high as $35.09, with a base case around $23.84 and support toward $17.49 — roughly +83% from $13.00. Buyers look set to stay in control over this stretch.
Expect ANL to range from $20.49 to $46.41 through 2028. The $29.61 average target implies a +128% move from current prices. That is up +24% on the projected 2027 average. Momentum favours further upside here.
The ANL price prediction for 2029 points to an average of $31.57 (low $20.78, high $51.91) — a potential gain of +143% on today's $13.00. Buyers look set to stay in control over this stretch.
In 2030, ANL is projected to trade between $22.06 and $59.95, averaging $35.06 — a potential gain of +170% from today's $13.00. That is up +11% on the projected 2029 average. Momentum favours further upside here.
Adlai Nortye Ltd.'s 2031 outlook centres on $38.31, within a $23.12 to $67.79 range. That is up +9% on the projected 2030 average. That marks a +195% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ANL could reach as high as $76.98, with a base case around $42.22 and support toward $24.48 — roughly +225% from $13.00. Momentum favours further upside here.
Expect ANL to range from $34.28 to $115.06 through 2033. The $61.43 average target implies a +373% move from current prices. That is up +45% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ANL price prediction for 2034 points to an average of $76.02 (low $40.87, high $145.92) — a potential gain of +485% on today's $13.00. Momentum favours further upside here.
In 2035, ANL is projected to trade between $42.77 and $161.95, averaging $82.48 — a potential gain of +534% from today's $13.00. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Adlai Nortye Ltd.'s 2040 outlook centres on $133.12, within a $59.91 to $286.77 range. That is up +61% on the projected 2035 average. That marks a +924% change versus current levels. Momentum favours further upside here.
By 2050, ANL could reach as high as $613.60, with a base case around $266.78 and support toward $120.05 — roughly +19.5x from $13.00. Buyers look set to stay in control over this stretch.
Investing $1,000 in ANL today (≈ 76.923077 ANL) could be worth
$20,521.66
+$19,521.66 (+1952%) by 2050 · US Dollar
Based on the average projected ANL price of $266.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANLwould be worth at today's price.
$1,000 invested in ANL on Jul 31, 2025 (≈ 699.300725 ANL) would be worth
$9,090.91
+$8,090.91 (+809.1%) today · 9.09× · US Dollar
Based on a ANL entry price of $1.43 vs. today's $13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.5 | $1,040 | +4.0% |
| 1 month ago | $10.6 | $1,226.42 | +22.6% |
| 3 months ago | $15.5 | $838.71 | -16.1% |
| 6 months ago | $9.27 | $1,402.37 | +40.2% |
| 1 year ago | $1.43 | $9,090.91 | +809.1% |
| All time (2.8y) ago | $15 | $866.67 | -13.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANL forecast.
Our base-case forecast reaches $26.00 around 2028.
Implied market cap at $26.00: $1.53B
The multi-year forecast points to strong upside potential, with the average price rising from $13.00 in 2026 to $270.66 by 2050. In 2030 the avg price is $35.70 with a 174.6% ROI, and by 2040 the avg price is $134.53 with a 934.8% ROI. The 2050 forecast projects an average of $270.66 and a max of $622.52, with a 1982% ROI and a bullish sentiment.
The trajectory implies meaningful appreciation across the horizon, tempered by inherent market uncertainty and the usual risks associated with clinical-stage biotechnology exposure. These are estimates, not guarantees, and should be considered within the broader risk landscape of high-growth healthcare investments.
Tap a question to reveal the answer.
2030 avg $35.70; min $22.19; max $61.68; ROI 174.6; sentiment BULLISH.
The forecast shows a neutral stance in 2026 (avg $13.00, ROI 0) with a shifting bullish trajectory in subsequent years (2030 avg $35.70, ROI 174.6; 2040 avg $134.53, ROI 934.8; 2050 avg $270.66, ROI 1982), indicating substantial upside over time, albeit with uncertainty typical of biotechnology stocks.
Yes. The max forecast price reaches $294.04 by 2040 and $622.52 by 2050, indicating potential to exceed $100 in the long term.
2026 min $1.38; 2027 min $17.65.
Current price $13.00; Market cap $837.17M.
Adlai Nortye Ltd. Community Discussion
0Share your Adlai Nortye Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.